Tag: Bharat BioTech

On Republic Day, Bharat Biotech launches first India-made nasal Covid vaccine

"Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today dedicated iNCOVACC® (BBV154) to the nation, the world's 1st COVID intranasal vaccine for Primary series and Heterologous booster," read a release issued by the firm on Thursday.

January 26, 2023

Nasal Covid vaccine to be sold at Rs 800 at pvt & Rs 325 at govt hospitals, GST to be levied

The Union Health Ministry said that those who have taken Covishield and Covaxin could take the nasal vaccine as a heterologous booster dose. The iNCOVACC has been approved by the Government of India and will be used as a heterologous booster dose for those above 18 years of age.

December 27, 2022

Centre approves Bharat Biotech’s nasal Covid vaccine for booster dose

The nasal vaccine BBV154 had received approval from the Drugs Controller General of India in November for restricted use in an emergency situation for those above 18 as a heterologous booster dose.

December 23, 2022

Centre approves Bharat Biotech’s intranasal Covid vaccine for booster

The nassal vaccine has been approved for those aged above 18 years. The vaccine will be available in the private hospitals for booster dose in the initial phase.

December 23, 2022

Bharat Biotech evinces interest to invest in Karnataka

Ella, Chairman, and MD of Bharat Biotech, which produces Covaxin, met state Minister for Large and Medium Industries Dr. Murugesh R. Nirani, in Hyderabad on Friday, stated the official press release from the ministry of large and medium industries.

October 14, 2022

India approves its first nasal vaccine for Covid

The new inoculation was developed by Bharat Biotech, which had already developed an intravenous product greenlit by the World Health Organization last November.

September 7, 2022

India’s first intranasal vaccine for Covid gets DCGI approval

India's first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation.

September 6, 2022

Diligently working with WHO to obtain EUL for Covaxin: Bharat Biotech

The WHO's EUL approval for Covaxin was expected by 5 October as WHO's Strategic Advisory Group of Experts on Immunization (SAGE) was scheduled to meet on this day to make its recommendations on Bharat Biotech's Covaxin for Emergency Use Listing. The process has been delayed as more technical data has been sought from the pharma major.

September 28, 2021

Mansukh Mandaviya releases first commercial batch of COVAXIN manufactured in Ankleshwar, Gujarat

The National Covid-19 Vaccination Programme has been successfully going on across all states and Union Territories since 16th January, 2021, he added.

August 29, 2021

IIL hands over first batch of Covaxin drug substance to Bharat Biotech

In order to augment the Covid-19 vaccine production capacity in the country, the Central government in April requested that the IIL and Bharat Biotech International Ltd (BBIL) join hands.

August 13, 2021

Bharat Biotech’s Rotavac 5D receives WHO prequalification

The new variant of Rotavac is a unique rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 ml) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children.

August 2, 2021

Review process begins for WHO listing of Covaxin: Bharat Biotech

Bharat Biotech chairman and managing director, Krishna Ella, said all documents required for EUL of Covaxin, have been submitted to WHO as of July 9.

July 12, 2021

Centre caps 20% of Covaxin supply for first dose beneficiaries, registration allowed only via CoWIN

So far, Covaxin's supply has roughly contributed only 10 per cent of the total doses administered in the nationwide Covid-19 immunisation programme.

July 10, 2021

Bharat Biotech dispatches Covaxin to 16 states

The company's co-founder and joint managing director Suchitra Ella on Wednesday tweeted that Andhra Pradesh, Assam, Delhi, Gujarat, Karnataka, Madhya Pradesh, Maharashtra, Tamil Nadu, and Telangana were supplied the vaccines through the government of India from June 8 to 14.

June 16, 2021

Rs 150/dose for Covaxin not sustainable: Bharat Biotech

The Hyderabad-based vaccine manufacturing company said a higher price in private markets is required to offset part of the costs.

June 15, 2021

Indian govt, Poonawalla refute reports about no vaccine orders

The media reports suggested that the last order placed with the two vaccine makers (100 million doses with SII and 20 million doses with Bharat Biotech) was in March.

May 3, 2021

Biotech slashes Covaxin price for states to 400/jab

Serum Institute on Wednesday slashed the price of its Covishield vaccine to Rs 300 per dose from the earlier Rs 400 for states.

April 30, 2021